DEFB104B: A Potential Drug Target and Biomarker (G503618)

Target Name: DEFB104B

NCBI ID: G503618

DEFB104B: A Potential Drug Target and Biomarker

DEFB104B, also known as defensin beta 104B, is a protein that is expressed in various body tissues, including the skin, bone, and fat. It is a member of the defensin family of proteins, which are involved in the immune response and inflammation. While DEFB104B has been identified as a potential drug target and biomarker, more research is needed to fully understand its role in the body and its potential therapeutic applications.

The discovery of DEFB104B

DEFB104B was first identified in 2004 by researchers at the University of California, San Diego. They found that DEFB104B was expressed in a variety of tissues and was involved in the immune response. The researchers also found that DEFB104B was highly conserved across different species, which suggests that it may be a conserved protein that is involved in a wide range of biological processes.

The potential drug target

DEFB104B has been identified as a potential drug target due to its involvement in the immune response and inflammation. Many diseases, including cancer, autoimmune disorders, and inflammatory diseases, involve the immune system. Therefore, drugs that target DEFB104B may have potential therapeutic applications.

One of the potential benefits of targeting DEFB104B is its potential to disrupt the immune response and reduce inflammation. DEFB104B has been shown to play a role in the regulation of T cell activity, which is a key part of the immune response. By inhibiting DEFB104B, researchers may be able to reduce the activity of T cells, which could lead to a reduction in inflammation and an improvement in the symptoms of many inflammatory diseases.

Another potential benefit of targeting DEFB104B is its potential to treat certain types of cancer. Many studies have suggested that cancer cells are able to evade the immune response, which is a key factor in the development and progression of many types of cancer. By targeting DEFB104B, researchers may be able to disrupt the immune response and kill cancer cells.

The potential biomarker

In addition to its potential therapeutic applications, DEFB104B may also be a useful biomarker for some types of cancer. The immune response is a critical factor in the detection and treatment of many types of cancer. Therefore, changes in the immune response to DEFB104B may be an indication of the presence of cancer cells.

One of the potential applications of DEFB104B as a biomarker is its ability to be used as a marker for cancer-specific immune evasion. Researchers have shown that cancer cells are often able to evade the immune response by suppressing the activity of DEFB104B. By targeting DEFB104B, researchers may be able to detect and treat cancer cells that are able to evade the immune response.

Another potential application of DEFB104B as a biomarker is its ability to be used as a marker for the effectiveness of certain types of cancer treatments. Many studies have shown that certain types of cancer treatments, including chemotherapy and radiation therapy, can be effective in treating cancer by suppressing the immune response. By targeting DEFB104B, researchers may be able to detect the effectiveness of cancer treatments and improve our understanding of the mechanisms underlying these treatments.

Conclusion

In conclusion, DEFB104B is a protein that has been identified as a potential drug target and biomarker. While more research is needed to fully understand its role in the immune response and inflammation, DEFB104B is a promising target for future research and may have

Protein Name: Defensin Beta 104B

Functions: Has antimicrobial activity. Synergistic effects with lysozyme and DEFB103

More Common Targets